BioPharmSignal logoBioPharmSignal

Biotech News

AN2 Therapeutics to Participate at Upcoming Investor Conferences

AN2 Therapeutics (ANTX)AN2 TherapeuticsCompany update

MENLO PARK, Calif. --(BUSINESS WIRE)--Oct. 20, 2026-- AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced company management will participate in

Related news

ANTXAN2 Therapeutics2026-05-07 20:01 EST

AN2 Therapeutics to Participate in 2026 Stifel Virtual Targeted Oncology Forum

ANTXAN2 Therapeutics2026-10-23 21:00 EST

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

IMNNImunon2026-10-08 13:00 EST

IMUNON to Participate in Upcoming Investor Conferences

SCYXSCYNEXIS2026-09-01 12:30 EST

SCYNEXIS to Participate in Upcoming Investor Conferences

ENTAEnanta Pharmaceuticals2026-09-01 11:00 EST

Enanta Pharmaceuticals to Participate in September Investor Conferences

SPROSpero Therapeutics2026-10-15 21:05 EST

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

VIRIVirios Therapeutics2026-10-06 12:45 EST

Dogwood to Participate in the 2026 Maxim Growth Summit

SPROSpero Therapeutics2026-10-02 21:05 EST

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VIRIVirios Therapeutics2026-06-30 12:45 EST

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

View all latest news

AN2 Therapeutics

Boron-Based Drug Development AN2 Therapeutics develops small-molecule medicines derived from its boron chemistry expertise, with programs spanning hematology, infectious disease, and oncology. Epetraborole in Polycythemia Vera AN2 is preparing the EBO-PV-201 Phase 2 proof-of-concept study of epetraborole in phlebotomy-dependent...

Recent company news

ANTXAN2 Therapeutics2026-10-23 21:00 EST

AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4)

ANTXAN2 Therapeutics2026-10-21 11:00 EST

AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms

ANTXAN2 Therapeutics2026-10-20 20:13 EST

AN2 Therapeutics to Participate at Upcoming Investor Conferences

ANTXAN2 Therapeutics2026-09-28 11:00 EST

AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK

ANTXAN2 Therapeutics2026-09-16 21:33 EST

AN2 Therapeutics, Inc. Reports Inducement Grants under Listing Rule 5635(c)(4)

Stock data

Close
3.64 USD
Market cap
146.59M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States